Yes, AXON is overvalued, don't have close to CTIX potential. CTIX is undervalued like you say, but additional cash upfront from a license would push the stock price and maybe uplist. A license deal needs to be done when B-ABSSI starts. Maybe beginning milestones can be based on that interim analysis of 200 patients. The market CTIX trades on can't be lived on forever. There are no analysts at this level or institutions to invest. I hope these proposed hirings are for certain, but they won't push stock price to proper valuation----Need cash...stop tapping Aspire and eventual uplist.